CSPC Innovation Pharma, CSPC Pharmaceutical Group unit, forecasts H1 net profit at 1.18 billion-1.36 billion yuan

PUBT · 2d ago
CSPC Innovation Pharma, CSPC Pharmaceutical Group unit, forecasts H1 net profit at 1.18 billion-1.36 billion yuan
  • CSPC Innovation Pharmaceutical, a subsidiary of CSPC Pharmaceutical Group, guided for H1 2026 net profit attributable to shareholders of CNY 1.18-1.36 billion.
  • That compares with a net loss of CNY 2.75 million a year earlier.
  • Net profit after deducting non-recurring items seen at CNY 1.15-1.33 billion versus a loss of CNY 41.14 million.
  • Turnaround driven by revenue recognition from a US$420 million AstraZeneca upfront payment received on May 29.
  • Commercial rollout advanced for Enlonstobart Injection, Omalizumab for Injection, Ustekinumab Injection.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CSPC Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260727-12257425), on July 27, 2026, and is solely responsible for the information contained therein.